Catecholamine Turnover in Normotensive and Hypertensive Man: Effects of Antiadrenergic Drugs
Overview
Authors
Affiliations
Intravenous administration of tritium-labeled 3,4-dihydroxyphenylalanine (dopa) to human subjects resulted in the labeling of endogenous catecholamines and vanillylmandelic acid (VMA). Determination of the changes in specific activity of these compounds with time in fractional collections of urine and in cardiac biopsies from patients undergoing corrective cardiac surgery permitted estimation of apparent turnover rates. The average half-time of the exponential decline in specific activity of labeled urinary norepinephrine was about 8 hr and that of VMA was 11-16 hr in five normal subjects. No significant differences from normal were observed in eight patients with essential hypertension. The average half-life of norepinephrine was only 5 hr in cardiac patients undergoing surgery, and the levels and rate of decline of cardiac norepinephrine specific activity correlated well with the exponential phase of the urinary disappearance curve. There were significant effects of treatment with alpha-methyltyrosine, reserpine, and pargyline hydrochloride on the labeling and apparent turnover rates of norepinephrine and VMA; the effects noted were consistent with known actions of these three drugs. It is suggested that the technique used is a suitable means of assessing "over-all" catecholamine metabolism in man, particulary if combined with quantitative assay of urinary catecholamine metabolites.
alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.
Brogden R, Heel R, Speight T, Avery G Drugs. 1981; 21(2):81-9.
PMID: 7009139 DOI: 10.2165/00003495-198121020-00001.
Human norepinephrine metabolism. Its evaluation bydministration of tritiated norepinephrine.
GITLOW S, MENDLOWITZ M, Bertani L, Wilk S, Wilkek J Clin Invest. 1971; 50(4):859-65.
PMID: 5547279 PMC: 292000. DOI: 10.1172/JCI106557.
Nikodijevic B, TRAJKOV T, Glavas E, Gudeska S, Vetadzokoska D Naunyn Schmiedebergs Arch Pharmakol. 1971; 268(2):185-91.
PMID: 4250810 DOI: 10.1007/BF01020073.
Brecht H, Banthien F, SCHOEPPE W Klin Wochenschr. 1976; 54(22):1095-105.
PMID: 1003867 DOI: 10.1007/BF01469113.
Acebutolol in hypertension--double-blind trial against placebo.
Martin M, Phillips C, Smith A Br J Clin Pharmacol. 1978; 6(4):351-6.
PMID: 359018 PMC: 1429467. DOI: 10.1111/j.1365-2125.1978.tb00863.x.